skip to main content
Idioma:
Refinado por: Nome da Publicação: Blood remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Yacoub, Abdulraheem ; Mascarenhas, John ; Kosiorek, Heidi ; Prchal, Josef T. ; Berenzon, Dmitry ; Baer, Maria R. ; Ritchie, Ellen ; Silver, Richard T. ; Kessler, Craig ; Winton, Elliott ; Finazzi, Maria Chiara ; Rambaldi, Alessandro ; Vannucchi, Alessandro M. ; Leibowitz, David ; Rondelli, Damiano ; Arcasoy, Murat O. ; Catchatourian, Rosalind ; Vadakara, Joseph ; Rosti, Vittorio ; Hexner, Elizabeth ; Kremyanskaya, Marina ; Sandy, Lonette ; Tripodi, Joseph ; Najfeld, Vesna ; Farnoud, Noushin ; Papaemmanuil, Elli ; Salama, Mohamed ; Singer-Weinberg, Rona ; Rampal, Raajit ; Goldberg, Judith D. ; Barbui, Tiziano ; Mesa, Ruben ; Dueck, Amylou C. ; Hoffman, Ronald

Blood, 2019-10, Vol.134 (18), p.1498-1509 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
2
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Mascarenhas, John ; Kosiorek, Heidi E. ; Prchal, Josef T. ; Rambaldi, Alessandro ; Berenzon, Dmitriy ; Yacoub, Abdulraheem ; Harrison, Claire N. ; McMullin, Mary Frances ; Vannucchi, Alessandro M. ; Ewing, Joanne ; O'Connell, Casey L. ; Kiladjian, Jean-Jacques ; Mead, Adam J. ; Winton, Elliott F. ; Leibowitz, David S. ; De Stefano, Valerio ; Arcasoy, Murat O. ; Kessler, Craig M. ; Catchatourian, Rosalind ; Rondelli, Damiano ; Silver, Richard T. ; Bacigalupo, Andrea ; Nagler, Arnon ; Kremyanskaya, Marina ; Levine, Max F. ; Arango Ossa, Juan E. ; McGovern, Erin ; Sandy, Lonette ; Salama, Mohamad E. ; Najfeld, Vesna ; Tripodi, Joseph ; Farnoud, Noushin ; Penson, Alexander V. ; Weinberg, Rona Singer ; Price, Leah ; Goldberg, Judith D. ; Barbui, Tiziano ; Marchioli, Roberto ; Tognoni, Gianni ; Rampal, Raajit K. ; Mesa, Ruben A. ; Dueck, Amylou C. ; Hoffman, Ronald

Blood, 2022-05, Vol.139 (19), p.2931-2941 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
3
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings
Material Type:
Artigo 		Adicionar ao Meu Espaço

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Yacoub, Abdulraheem ; Mascarenhas, John ; Mesa, Ruben A. ; Kosiorek, Heidi E. ; Rampal, Raajit K. ; Silver, Richard T. ; Salama, Mohamed E. ; Siwoski, Olivia ; Dueck, Amylou C. ; Sandy, Lonette ; McMullin, Mary Frances ; Ewing, Joanne ; O'Connell, Casey L. ; Mead, Adam J. ; De Stefano, Valerio ; Weinberg, Rona Singer ; Baer, Maria R. ; Kessler, Craig M. ; Winton, Elliott F. ; Vannucchi, Alessandro M. ; Kremyanskaya, Marina ; Vadakara, Joseph ; Rosti, Vittorio ; Hexner, Elizabeth O. ; Rondelli, Damiano ; Arcasoy, Murat O. ; Rambaldi, Alessandro ; Ritchie, Ellen K. ; Barbui, Tiziano ; Kiladjian, Jean-Jacques ; Harrison, Claire N ; Prchal, Josef T. ; Hoffman, Ronald

Blood, 2019-11, Vol.134 (Supplement_1), p.2943-2943 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
4
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Mesa, Ruben A. ; Kosiorek, Heidi E. ; Mascarenhas, John ; Prchal, Josef T. ; Rambaldi, Alessandro ; Berenzon, Dmitriy ; Yacoub, Abdulraheem ; Harrison, Claire N. ; McMullin, Mary Frances ; Vannucchi, Alessandro M. ; Ewing, Joanne ; O'Connell, Casey L. ; Kiladjian, Jean-Jacques ; Mead, Adam J. ; Winton, Elliott F. ; Leibowitz, David S. ; De Stefano, Valerio ; Arcasoy, Murat O. ; Kessler, Craig M. ; Catchatourian, Rosalind ; Rondelli, Damiano ; Silver, Richard T. ; Bacigalupo, Andrea ; Nagler, Arnon ; Kremyanskaya, Marina ; Sandy, Lonette ; Salama, Mohamed E. ; Najfeld, Vesna ; Tripodi, Joseph ; Weinberg, Rona Singer ; Rampal, Raajit K. ; Hoffman, Ronald ; Dueck, Amylou C.

Blood, 2018-11, Vol.132 (Supplement 1), p.3032-3032 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
5
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Mascarenhas, John ; Kosiorek, Heidi E. ; Prchal, Josef T. ; Rambaldi, Alessandro ; Berenzon, Dmitriy ; Yacoub, Abdulraheem ; Harrison, Claire N. ; McMullin, Mary Frances ; Vannucchi, Alessandro M. ; Ewing, Joanne ; O'Connell, Casey L. ; Kiladjian, Jean-Jacques ; Mead, Adam J. ; Winton, Elliott F. ; Leibowitz, David S. ; De Stefano, Valerio ; Arcasoy, Murat O. ; Kessler, Craig M. ; Catchatourian, Rosalind ; Rondelli, Damiano ; Silver, Richard T. ; Bacigalupo, Andrea ; Nagler, Arnon ; Kremyanskaya, Marina ; Sandy, Lonette ; Salama, Mohamed E. ; Najfeld, Vesna ; Tripodi, Joseph ; Weinberg, Rona Singer ; Price, Leah ; Goldberg, Judith D ; Rampal, Raajit K. ; Mesa, Ruben A. ; Dueck, Amylou C. ; Hoffman, Ronald

Blood, 2018-11, Vol.132 (Supplement 1), p.577-577 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial
Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Dueck, Amylou C. ; Mascarenhas, John ; Kosiorek, Heidi Elizabeth ; Yacoub, Abdulraheem ; Prchal, Josef T. ; Berenzon, Dmitriy ; Baer, Maria R. ; Ritchie, Ellen K ; Silver, Richard T ; Kessler, Craig M. ; Winton, Elliott F. ; Finazzi, Maria Chiara ; Rambaldi, Alessandro ; Vannucchi, Alessandro M. ; Leibowitz, David S. ; Rondelli, Damiano ; Arcasoy, Murat O. ; Catchatourian, Rosalind ; Vadakara, Joseph ; Rosti, Vittorio ; Hexner, Elizabeth ; Kremyanskaya, Marina ; Orellana, Alicia ; Sandy, Lonette ; Tripodi, Joseph ; Najfeld, Vesna ; Salama, Mohamed E. ; Weinberg, Rona Singer ; Rampal, Raajit K. ; Hoffman, Ronald ; Mesa, Ruben A

Blood, 2017-12, Vol.130, p.4206-4206 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
7
Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial
Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Yacoub, Abdulraheem ; Mascarenhas, John ; Kosiorek, Heidi Elizabeth ; Prchal, Josef T. ; Berenzon, Dmitriy ; Baer, Maria R. ; Ritchie, Ellen K ; Silver, Richard T ; Kessler, Craig M. ; Winton, Elliott F. ; Finazzi, Maria Chiara ; Rambaldi, Alessandro ; Vannucchi, Alessandro M. ; Leibowitz, David S. ; Rondelli, Damiano ; Arcasoy, Murat O. ; Catchatourian, Rosalind ; Vadakara, Joseph ; Rosti, Vittorio ; Hexner, Elizabeth ; Kremyanskaya, Marina ; Orellana, Alicia ; Sandy, Lonette ; Tripodi, Joseph ; Najfeld, Vesna ; Salama, Mohamed E. ; Weinberg, Rona Singer ; Rampal, Raajit K. ; Mesa, Ruben A ; Goldberg, Judith D ; Dueck, Amylou C. ; Hoffman, Ronald

Blood, 2017-12, Vol.130, p.321-321 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
8
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia

Mascarenhas, John O. ; Prchal, Josef T. ; Rambaldi, Alessandro ; Mesa, Ruben A. ; Berenzon, Dmitriy ; Yacoub, Abdulraheem ; Harrison, Claire N. ; McMullin, Mary Frances ; Vannucchi, Alessandro M. ; Ewing, Joanne C ; O'Connell, Casey L ; Kiladjian, Jean-Jacques ; Mead, Adam ; Winton, Elliott F. ; Leibowitz, David S. ; De Stefano, Valerio ; Arcasoy, Murat O. ; Kessler, Craig M. ; Catchatorian, Rosalind ; Rondelli, Damiano ; Silver, Richard T. ; Ritchie, Ellen K. ; Nagler, Arnon ; Kremyanskaya, Marina ; Schlenk, Richard F. ; Weinberg, Rona Singer ; Salama, Mohamed E ; Tognoni, Gianni ; Prosperini, Giuseppe ; Di Lelio, Alessandra ; Serone, Eliseo ; Marfisi, Lorenzo ; Kleczko, Jill ; Kosiorek, Heidi E. ; Barbui, Tiziano ; Dueck, Amylou C. ; Hoffman, Ronald

Blood, 2016-12, Vol.128 (22), p.479-479 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
9
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Mesa, Ruben A. ; Hoffman, Ronald ; Kosiorek, Heidi E. ; Prchal, Josef T. ; Harrison, Claire N. ; McMullin, Mary Frances ; Yacoub, Abdulraheem ; Rambaldi, Alessandro ; Berenzon, Dmitriy ; Vannucchi, Alessandro M. ; Ewing, Joanne C ; O'Connell, Casey L ; Kiladjian, Jean-Jacques ; Mead, Adam ; Winton, Elliott F. ; Leibowitz, David S. ; De Stefano, Valerio ; Arcasoy, Murat O. ; Kessler, Craig M. ; Catchatorian, Rosalind ; Rondelli, Damiano ; Silver, Richard T. ; Ritchie, Ellen K. ; Nagler, Arnon ; Kremyanskaya, Marina ; Schlenk, Richard F. ; Weinberg, Rona Singer ; Salama, Mohamed E ; Tognoni, Gianni ; Prosperini, Giuseppe ; Di Lelio, Alessandra ; Serone, Eliseo ; Marfisi, Lorenzo ; Orellana, Alicia ; Barbui, Tiziano ; Dueck, Amylou C. ; Mascarenhas, John O.

Blood, 2016-12, Vol.128 (22), p.4271-4271 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
10
Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America
Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America

Flowers, Christopher R. ; Lill, Michael ; Costa, Luciano J ; Shore, Tsiporah B. ; Vaughan, William ; Craig, Michael ; Freytes, Cesar O. ; Shea, Thomas C. ; Horwitz, Mitchell E. ; Fay, Joseph W. ; Mineishi, Shin ; Rondelli, Damiano ; Mason, James ; Reddy, Vijay ; Braunschweig, Ira ; Ai, Weiyun ; Armstrong, Elizabeth ; Smith, Angela ; Zhao, Cathy ; Elekes, Agnes ; Kato, Kazunobu ; Waller, Edmund K.

Blood, 2013-11, Vol.122 (21), p.768-768 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.